subtype was less prevalent (36 percent vs. 59 percent-54 percent, respectively). The HER2+/ER- subtype did not vary with race or menopausal status (6 percent-9 percent). In this cohort of patients diagnosed between 1993-96, breast cancerspecific survival differed by subtype, with shortest survival among HER2+/ER- and basal-like subtypes. The basal-like subtype is sensitive to chemotherapy, however unlike the other subtypes there are currently no targeted treatment options for this subtype.

"The high prevalence of basal-like tumors in younger African American women could contribute to their higher breast cancer mortality. Additional studies of long-term survival among patients with specific breast cancer subtypes are needed. Clinical trials aimed at identifying therapeutic approaches to the management of basal-like breast cancer are also needed, especially for young African American women," the authors conclude.

'"/>

Contact: Tom Hughes
919-741-8840
JAMA and Archives Journals
6-Jun-2006

Page: 1 2
Related medicine news :

1. Case study: cross-cultural bioethics training program helps fight African brain drain
2. African-American men understimate risk of prostate cancer
3. New AIDS Tech Transfers reinforce Roche commitment to strengthen African manufacturing
4. Limiting eligibility for medical studies can omit women and African-Americans
5. Certain combination therapy found more effective for treating malaria in African children
6. Number of insecticide-treated nets available to African households needs to be increased
7. African-Americans perceive people with extreme health problems as less productive and valuable
8. Hair straightening chemicals not linked to breast cancer risk in African-Americans
9. Survey reveals misperceptions about Alzheimers among African-American and Hispanic caregivers
10. Undergrad: Mothers in African study undereducated on diarrhea
11. African scientists will train at Emory University in latest drug discovery techniques